Evommune, Inc. (EVMN)
12.02
+0.02
(+0.12%)
USD |
NYSE |
Sep 04, 11:29
Evommune Cash from Investing (Quarterly) : 31.29M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.29M |
| March 31, 2026 | -85.36M |
| December 31, 2025 | -122.90M |
| September 30, 2025 | -23.91M |
| June 30, 2025 | 18.00M |
| Date | Value |
|---|---|
| March 31, 2025 | 13.50M |
| September 30, 2024 | 9.412M |
| June 30, 2024 | 10.03M |
| March 31, 2024 | 9.648M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 60.70M |
| Mineralys Therapeutics, Inc. | -185.22M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.32M |
| Cash from Financing (Quarterly) | 0.532M |
| Free Cash Flow | -74.65M |
| Free Cash Flow Per Share (Quarterly) | -0.5673 |
| Free Cash Flow to Equity (Quarterly) | -20.01M |
| Free Cash Flow to Firm (Quarterly) | -20.50M |
| Free Cash Flow Yield | -18.71% |